Skip to content

Author

S. O'Bryant

We have 7 of 494 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Plasma P-tau217, APOE Genotype, and the Timing of Cognitive Impairment in individuals Across Diverse Racial and Ethnic Groups: A Pooled Analysis of Prospective Cohort Studies

Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.

Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al. · 1 citation
Open access Aug 2026

Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts

A multi-dimensional attention framework that simultaneously captures both temporal dynamics and biomarker importance to predict disease progression across three fundamentally different populations could enable precision medicine approaches for data-limited cohorts across the Alzheimer's disease spectrum.

Zhi-Yuan Song, Si-Yang Song, Isabel C. H. Clare et al. · 0 citations
Open access Sep 2026

Metabolic dysfunction associates with neuroimaging measures of brain structure and connectivity

Network-specific associations between cardiometabolic risk and DMN organization are suggested to be detectable in indi viduals with MCI, a clinical state preceding dementia, as well as in some degree within cognitively unimpaired individuals.

Zachary D. Green, S. O'Bryant, L. Johnson et al. · 0 citations
Open access Aug 2026

Diabetes and neurodegeneration in cognitively unimpaired older adults: implications for cognition.

Diabetes-related cortical thinning in cognitively unimpaired older adults follows a regional pattern independent of Alzheimer's and cerebrovascular pathology and partially mediates accelerated decline in processing speed, suggesting chronic hyperglycemia may contribute to diabetes-related neurodegeneration, regardless...

A. Tsiknia, Victoria R. Tennant, Marylan Davison et al. · 1 citation
Open access Jul 2026

Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.

Higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline, and support the potential of p-tau217 for prognostic model development, with direct implications for future trial design.

R. Buckley, D. Townsend, C. Birkenbihl et al. · 3 citations
Open access Jul 2026

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

A double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use, and positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads).

G. Blazhenets, D. Soleimani-Meigooni, Konstantinos Chiotis et al. · 5 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.